[{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||SPHK2","graph1":"Oncology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Ben-Gurion University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"P-Esbp Conjugated Doxorubicin","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Ben-Gurion University","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Ben-Gurion University"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Insightec","sponsor":"SonALAsense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Insightec \/ SonALAsense","highestDevelopmentStatusID":"4","companyTruncated":"Insightec \/ SonALAsense"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GDA-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Public Offering","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Silexion Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Evonik","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Silexion Therapeutics \/ Evonik","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Evonik"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Myeloma Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2022","type":"Financing","leadProduct":"DSP107","moa":"CD47\/41BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Myeloma Investment Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medical \/ Myeloma Investment Fund"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"Isotopia","sponsor":"Philochem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"177-Lu OncoFAP-23","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotopia \/ Philochem","highestDevelopmentStatusID":"4","companyTruncated":"Isotopia \/ Philochem"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Bar-Ilan University"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MOSPD2","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"DSP502","moa":"DSP-Fc","graph1":"Oncology","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kahr Medical \/ Thomas Jefferson University","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medical \/ Thomas Jefferson University"},{"orgOrder":0,"company":"PolyPid","sponsor":"ImmunoGenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"IMGS-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ ImmunoGenesis","highestDevelopmentStatusID":"4","companyTruncated":"PolyPid \/ ImmunoGenesis"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MUC1-SP-L","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Inapplicable"},{"orgOrder":0,"company":"MitoCareX Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SLC25","graph1":"Oncology","graph2":"Preclinical","graph3":"MitoCareX Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoCareX Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MitoCareX Bio \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Aramchol meglumine","moa":"SCD1","graph1":"Oncology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pharmaceuticals \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL204","moa":"KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.

                          Product Name : SIL204

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          May 21, 2025

                          Lead Product(s) : SIL204

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The collaboration aims to evaluate Aramchol's (aramchol meglumine) effect on overcoming drug resistance in gastrointestinal (GI) cancers.

                          Product Name : Aramchol

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 17, 2025

                          Lead Product(s) : Aramchol meglumine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Virginia Commonwealth University

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : SIL204 is an innovative RNA interference (RNAi) therapies, which is currently being evaluated for the treatment of solid tumors driven by KRAS mutations.

                          Product Name : SIL-204

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 05, 2025

                          Lead Product(s) : SIL-204

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : SIL 204 is an anti KRAS G12D/V short-interfering RNA, which is being evaluated for KRAS G12D/V-mutated pancreatic neoplasms.

                          Product Name : SIL-204

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 25, 2025

                          Lead Product(s) : SIL-204

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : SIL-204 is a next-generation siRNA therapeutic candidate administered subcutaneously inhibited tumor growth in KRAS G12D/V-mutated pancreatic neoplasms mouse models.

                          Product Name : SIL-204

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          January 28, 2025

                          Lead Product(s) : SIL-204

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The net proceeds from the offering will advance the Company’s pre-clinical studies of SIL-204, which is being evaluated for KRAS G12D/V-mutated Pancreatic Neoplasms.

                          Product Name : SIL-204

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          January 15, 2025

                          Lead Product(s) : SIL-204

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $5.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : SIL 204 is an anti K-ras G12D/V short-interfering RNA, which is being evaluated for KRAS G12D/V-mutated Pancreatic neoplasms in combination with 5-fluorouracil and irinotecan.

                          Product Name : SIL-204

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          January 15, 2025

                          Lead Product(s) : SIL-204,Fluorouracil,Irinotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Company works on cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 07, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Through the collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation will used for SIL-204, Silexion’s siRNA candidate for KRAS mutated Pancreatic cancer.

                          Product Name : SIL-204

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          December 17, 2024

                          Lead Product(s) : SIL-204

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Evonik

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The collaboration aims to address the challenges of IMGS-501. These potent STING agonists are Being evaluated for the treatment of neoplasms.

                          Product Name : IMGS-501

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          November 12, 2024

                          Lead Product(s) : IMGS-501

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : ImmunoGenesis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank